Research
Bariatric surgery is effective rescue strategy after GLP-1 receptor agonist failure
The Brief
- A study published Nov. 3 in the Annals of Surgery links bariatric surgery to clinically meaningful two-year weight loss in patients who failed GLP-1 drugs.
- The reported benefit applies to people with semaglutide or tirzepatide intolerance or inadequate response.
- The finding is presented as an effective rescue option after GLP-1 receptor agonist failure.
Why it matters
Clinicians and researchers get evidence on a second-line option for patients who do not tolerate or respond to semaglutide or tirzepatide.
Who’s affected
- Patients with semaglutide or tirzepatide intolerance or inadequate response
- Bariatric surgery and obesity medicine clinicians
- #bariatric surgery
- #glp-1
- #obesity
- #weight loss
- #semaglutide
- #tirzepatide
Bariatric surgery is associated with clinically meaningful two-year weight loss after semaglutide or tirzepatide intolerance or inadequate response, according to a study published online Nov. 3 in the Annals of Surgery.
Timeline
Study published online in the Annals of Surgery
Medical Xpress - latest medical and health news stories
Bariatric surgery is effective rescue strategy after GLP-1 receptor agonist failure